IL4 and rheumatoid arthritis: Another study comprising a reduced number of early RA patients (n = 8) reported a correlation between a higher baseline percentage of IL-4 positive CD4+ T cells and low disease activity at six to nine months of MTX treatment [136], a finding in line with other data suggesting a relationship between a low IFN-/IL-4 ratio and better nine-month response to HCQ and SSZ [137].